Brief: Ryvu Therapeutics SA Says RVU120 Was Well Tolerated Across All Doses Evaluated

Ryvu Therapeutics SA

26/10/2022 09:19

Oct 26 (Reuters) - Ryvu Therapeutics SA  RVU.WA :
    * RYVU THERAPEUTICS PRESENTS UPDATED CLINICAL AND
PRECLINICAL DATA
ON RVU120 AT THE AACR-NCI-EORTC MOLECULAR TARGETS AND CANCER
THERAPEUTICS SYMPOSIUM
    * RYVU THERAPEUTICS - RVU120 WAS WELL TOLERATED ACROSS ALL
DOSES
EVALUATED
    * RYVU THERAPEUTICS - UPDATED DATA FROM PHASE I/II
DOSE-ESCALATION
STUDY OF RVU120 SHOW FOUR DISEASE STABILIZATIONS IN ADVANCED
SOLID TUMOR PATIENTS
    * RYVU THERAPEUTICS - PRECLINICAL DATA DEMONSTRATE THE
POTENTIAL
OF COMBINATION THERAPY WITH RVU120 AND ADCC-PROMOTING DRUGS
    * NOVEL MTA-COOPERATIVE PRMT5 INHIBITORS SHOW PRECLINICAL
ANTITUMOR EFFICACY AND TARGET ENGAGEMENT IN MTAP-DELETED CANCERS

Source text for Eikon:  ID:nGNX7S1ld0 
Further company coverage:  RVU.WA 
 ((Reuters.Briefs@thomsonreuters.com;))